UBS Group’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$133M Sell
545,548
-125,800
-19% -$29.3M 0.02% 841
2025
Q4
$139M Sell
671,348
-104,296
-13% -$20.6M 0.02% 782
2025
Q3
$144M Buy
775,644
+104,900
+16% +$18M 0.02% 775
2025
Q2
$102M Sell
670,744
-149,300
-18% -$22.9M 0.02% 940
2025
Q1
$136M Sell
820,044
-29,900
-4% -$4.68M 0.03% 722
2024
Q4
$123M Sell
849,944
-205,200
-19% -$31.8M 0.02% 789
2024
Q3
$171M Buy
1,055,144
+528,415
+100% +$84.2M 0.04% 476
2024
Q2
$77M Sell
526,729
-198,415
-27% -$29.5M 0.02% 775
2024
Q1
$115M Sell
725,144
-246,837
-25% -$39.3M 0.03% 585
2023
Q4
$152M Buy
971,981
+443,581
+84% +$68M 0.05% 403
2023
Q3
$82.3M Buy
528,400
+78,200
+17% +$12.9M 0.03% 580
2023
Q2
$74.5M Buy
450,200
+23,900
+6% +$3.86M 0.03% 624
2023
Q1
$66.1M Sell
426,300
-353,200
-45% -$57M 0.02% 645
2022
Q4
$138M Buy
779,500
+112,300
+17% +$19.4M 0.05% 375
2022
Q3
$109M Buy
667,200
+233,100
+54% +$39.4M 0.05% 404
2022
Q2
$77.1M Sell
434,100
-119,100
-22% -$21.2M 0.03% 534
2022
Q1
$98M Sell
553,200
-32,100
-5% -$5.46M 0.03% 528
2021
Q4
$100M Buy
585,300
+102,876
+21% +$16.8M 0.03% 600
2021
Q3
$77.9M Sell
482,424
-99,500
-17% -$17M 0.02% 636
2021
Q2
$95.9M Buy
581,924
+18,500
+3% +$3.06M 0.03% 536
2021
Q1
$92.6M Buy
563,424
+524
+0.1% +$84.8K 0.03% 550
2020
Q4
$88.6M Buy
562,900
+86,500
+18% +$12.8M 0.03% 524
2020
Q3
$70.9M Buy
476,400
+21,600
+5% +$3.2M 0.03% 508
2020
Q2
$64M Sell
454,800
-80,900
-15% -$11.8M 0.03% 508
2020
Q1
$70.2M Buy
535,700
+259,600
+94% +$36.8M 0.03% 442
2019
Q4
$40.3M Buy
276,100
+43,800
+19% +$5.94M 0.01% 896
2019
Q3
$30.1M Buy
232,300
+69,400
+43% +$9.14M 0.01% 972
2019
Q2
$22.7M Sell
162,900
-374,500
-70% -$51.8M 0.01% 1137
2019
Q1
$75.1M Sell
537,400
-210,500
-28% -$28.2M 0.03% 468
2018
Q4
$96.5M Buy
747,900
+368,000
+97% +$51.3M 0.04% 376
2018
Q3
$52.5M Buy
379,900
+291,400
+329% +$38.7M 0.02% 648
2018
Q2
$10.7M Sell
88,500
-110,200
-55% -$13.7M ﹤0.01% 1685
2018
Q1
$25.5M Buy
198,700
+32,000
+19% +$4.33M 0.01% 999
2017
Q4
$23.3M Sell
166,700
-10,600
-6% -$1.48M 0.01% 1092
2017
Q3
$23.1M Buy
177,300
+62,500
+54% +$8.29M 0.01% 1023
2017
Q2
$15.2M Buy
114,800
+82,400
+254% +$10.5M 0.01% 1230
2017
Q1
$4.04M Sell
32,400
-240,813
-88% -$28.8M ﹤0.01% 2273
2016
Q4
$31.5M Sell
273,213
-88,700
-25% -$10.2M 0.02% 756
2016
Q3
$42.8M Buy
361,913
+11,513
+3% +$1.4M 0.03% 590
2016
Q2
$42.5M Sell
350,400
-1,260,814
-78% -$143M 0.03% 559
2016
Q1
$174M Buy
1,611,214
+974,380
+153% +$101M 0.12% 190
2015
Q4
$65.4M Buy
636,834
+372,055
+141% +$37.4M 0.04% 419
2015
Q3
$24.7M Sell
264,779
-208,871
-44% -$20.2M 0.02% 770
2015
Q2
$46.2M Buy
473,650
+259,800
+121% +$26M 0.03% 554
2015
Q1
$21.5M Sell
213,850
-147,963
-41% -$15M 0.01% 907
2014
Q4
$37.8M Buy
+361,813
New +$38.1M 0.03% 658

Other funds holding JNJ

UBS Group's JNJ Position: Q1 2026 in Review

UBS Group increased its Johnson & Johnson (JNJ) stake by 2.3% in Q1 2026, buying an estimated $52.4M and bringing the position to 10,209,327 shares worth $2.5B. The position accounts for 0.37% of the portfolio, ranked #33.

UBS Group first reported a position in JNJ in Q4 2014 and has held it in 46 quarters since. 4,616 funds tracked by Wall St. Rank hold JNJ as of Q1 2026.

  • UBS Group held 10,209,327 shares of Johnson & Johnson worth $2.5B as of Q1 2026.
  • UBS Group bought 225,036 Johnson & Johnson shares in Q1 2026, an estimated $52.4M.
  • Johnson & Johnson made up 0.37% of UBS Group's portfolio in Q1 2026, its #33 holding.
  • UBS Group first reported a position in Johnson & Johnson in Q4 2014 and has held it in 46 quarters since.
  • 4,616 funds tracked by Wall St. Rank held Johnson & Johnson as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.